Chronicle Journal: Finance

Lilly jumps in with Vir, GSK on antibody drug combo against Covid

Vir's stock soared for the second day in a row, this time because it and partner GlaxoSmithKline disclosed a trial combining their monoclonal antibody with Lilly's authorized Covid-19 treatment.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.